Jaffetilchin Investment Partners LLC Grows Stake in PRA Health Sciences Inc (PRAH)

Jaffetilchin Investment Partners LLC lifted its stake in shares of PRA Health Sciences Inc (NASDAQ:PRAH) by 3.6% in the 4th quarter, HoldingsChannel reports. The fund owned 5,126 shares of the medical research company’s stock after acquiring an additional 177 shares during the quarter. Jaffetilchin Investment Partners LLC’s holdings in PRA Health Sciences were worth $471,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Raymond James & Associates boosted its position in shares of PRA Health Sciences by 18.6% in the fourth quarter. Raymond James & Associates now owns 38,644 shares of the medical research company’s stock worth $3,554,000 after buying an additional 6,058 shares during the period. Texas Permanent School Fund boosted its position in PRA Health Sciences by 5.0% during the fourth quarter. Texas Permanent School Fund now owns 38,267 shares of the medical research company’s stock valued at $3,519,000 after purchasing an additional 1,815 shares during the last quarter. Lyell Wealth Management LP acquired a new stake in PRA Health Sciences during the fourth quarter valued at $2,319,000. ETRADE Capital Management LLC boosted its position in PRA Health Sciences by 25.3% during the fourth quarter. ETRADE Capital Management LLC now owns 5,138 shares of the medical research company’s stock valued at $472,000 after purchasing an additional 1,036 shares during the last quarter. Finally, BlackRock Inc. boosted its position in PRA Health Sciences by 1.4% during the fourth quarter. BlackRock Inc. now owns 6,158,867 shares of the medical research company’s stock valued at $566,369,000 after purchasing an additional 84,557 shares during the last quarter. 99.96% of the stock is owned by institutional investors and hedge funds.

Get PRA Health Sciences alerts:

A number of research firms recently issued reports on PRAH. BidaskClub cut PRA Health Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, December 27th. Zacks Investment Research cut PRA Health Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. ValuEngine raised PRA Health Sciences from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. Robert W. Baird lifted their price objective on PRA Health Sciences from $119.00 to $122.00 and gave the company an “outperform” rating in a research report on Thursday. Finally, SunTrust Banks lifted their price objective on PRA Health Sciences to $120.00 and gave the company a “buy” rating in a research report on Monday, November 5th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $113.22.

PRAH opened at $108.72 on Friday. The firm has a market cap of $7.42 billion, a P/E ratio of 27.66, a PEG ratio of 1.42 and a beta of 1.14. PRA Health Sciences Inc has a 1 year low of $79.20 and a 1 year high of $121.98. The company has a quick ratio of 0.89, a current ratio of 0.89 and a debt-to-equity ratio of 1.22.

ILLEGAL ACTIVITY NOTICE: “Jaffetilchin Investment Partners LLC Grows Stake in PRA Health Sciences Inc (PRAH)” was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/4192668/jaffetilchin-investment-partners-llc-grows-stake-in-pra-health-sciences-inc-prah.html.

About PRA Health Sciences

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Read More: Fundamental Analysis – How It Helps Investors

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).